Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A controlled, assessor-blind, parallel groups, multicentre, multinational trial evaluating the immunogenicity of FE 999049 in repeated cycles of controlled ovarian stimulation in women undergoing an assisted reproductive technology programme

Trial Profile

A controlled, assessor-blind, parallel groups, multicentre, multinational trial evaluating the immunogenicity of FE 999049 in repeated cycles of controlled ovarian stimulation in women undergoing an assisted reproductive technology programme

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Oct 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Follitropin delta (Primary) ; Follitropin alfa
  • Indications Female infertility
  • Focus Pharmacodynamics; Registrational
  • Acronyms ESTHER-2
  • Sponsors Ferring Pharmaceuticals
  • Most Recent Events

    • 10 Oct 2018 Results of a pooled analysis assessing the neonatal outcome and incidence of congenital malformations following treatment with follitropin delta in phase III studies (ESTHER-1 and -2) presented at the American Society for Reproductive Medicine Scientific Congress 2018
    • 02 Jul 2018 Results published in the Ferring Pharmaceuticals Media Release
    • 27 Nov 2017 According to a Ferring Pharmaceuticals media release, based on the data from ESTHER programme, Swissmedic has approved Rekovelle(follitropin delta) for use in controlled stimulation for induction of the development of multiple follicles in women undergoing assisted reproductive technologies (ART), such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top